UK consumers reduced their purchases of food and alcoholic beverages this holiday season, with industry experts attributing the trend to the increased use of weight loss injections.
During the four weeks leading up to December 27, grocery sales reached £19.6 billion, marking a 2.5% rise from the previous year, as reported by market research firm NielsenIQ. Despite the revenue increase, sales volume experienced a slight decline of 0.2%.
Analysts in the retail sector suggest that the correlation between the drop in sales volume and the surge in GLP-1 injections usage, which mimic a satiety hormone, is evident. These injections, such as Mounjaro and Wegovy prescribed by the NHS for weight loss and Ozempic for diabetes, have been used by an estimated 1.6 million UK adults in the past year according to recent research from University College London.
Acknowledging this shift in consumer behavior, retail analyst Jonathan De Mello noted the impact of the “Ozempic effect” on grocery sales, emphasizing the need for retailers to adapt their product offerings to align with the trend of consuming less but higher-quality products.
Notable retailers have already responded to this trend by introducing smaller meal options. Co-op launched a range of “mini meals” catering to individuals with smaller appetites, while Marks & Spencer introduced a new “nutrient dense” product line, and Iceland expanded its frozen ready meal selection with 38 new items.
Leading supermarket executives, including Greggs’ CEO Roisin Currie, Tesco CEO Ken Murphy, and Sainsbury’s CEO Simon Roberts, have acknowledged the influence of weight loss medications on consumer preferences. They emphasized the importance of closely monitoring market trends and adapting to meet the changing demands of shoppers.
The impact of weight loss injections on consumer behavior has led to a noticeable shift in purchasing patterns, prompting retailers to rethink their product strategies to cater to the evolving needs of health-conscious consumers.
